Comparing inhaled glucocorticosteroids

Allergy: European Journal of Allergy and Clinical Immunology, Supplement

Volumn 54, Issue 49, 1999, Pages 42-50

  Pedersen, Soren ^a,b  

^a KOLDING HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

BECLOMETASONE DIPROPIONATE; BUDESONIDE; FLUNISOLIDE; FLUTICASONE; GLUCOCORTICOID; TIPREDANE; TRIAMCINOLONE ACETONIDE;

ADRENAL SUPPRESSION; ASTHMA; CONFERENCE PAPER; CORTICOSTEROID THERAPY; DOSE RESPONSE; DRUG BIOAVAILABILITY; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SAFETY; DRUG TOLERABILITY; GROWTH RETARDATION; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LIPOPHILICITY; OSTEOPOROSIS; POWDER INHALER; PRIORITY JOURNAL; RECEPTOR AFFINITY; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; ANTI-ASTHMATIC AGENTS; ASTHMA; CHILD; CHILD, PRESCHOOL; CLINICAL TRIALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOCORTICOIDS; HUMANS; METABOLIC CLEARANCE RATE; OUTCOME ASSESSMENT (HEALTH CARE); RECEPTORS, GLUCOCORTICOID; TREATMENT OUTCOME;

EID: 0033046291     PISSN: 01081675     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (51)

1. Harding SM. The human pharmacology of fluticasone propionate. Respir Med 1990;84 Suppl A:25-29.
2. Chaplin MD, Rooks W, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1996;27:402-413.
3. Mollmann H, Rohdewald P, Schmidt EW, Salomon V, Derendorf H. Pharmacokinetics of triamcinolone acetonide and its phosphate ester. Eur J Clin Fharmacol 1985;29:85-89.
4. Fuller R, Johnson M, Bye A. Fluticasone propionate an update on preclinical and clinical experience. Respir Med 1995;89 Suppl A;18.
5. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994;47:318-331.
6. Ryrfeldt A, Andersson P, Edsbacker S, Tonnesson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis Suppl 1982;122:86-95.
7. Pavord I, Knox A. Pharmacokinetic optimisation of inhaled steroid therapy in asthma. Clin Pharmacokinet 1993;25:126-135.
8. Zaborny BA, Lukacsko P, Barinov Colligon I, Ziemniak JA. Inhaled corticosteroids in asthma: a dose-proportionality study with triamcinolone acetonide aerosol. J Clin Pharmacol 1992;32:463-469.
9. Thorsson L, Dahlström K, Edsbäeker S, Källen A, Paulson J, Wiren JE. Pharmacokinetics and systemic effects of inhaled fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1997;43:155-161.
10. Thorsson L, Edsbäcker S, Conradson TB. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered dose inhaler P-MDI. Eur Respir J 1994;7:1839-1844.
11. Rohatagi S, Bye A, Mackie AE, Derendorf H. Mathematical modeling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci 1996;4:341-350.
12. Rohatayi S, Bye A, Falcoz C, et al. Dynamic modeling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996;36:938-941.
13. Rohatagi S, Hochhaus G, Mollmann H, et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:1187-1193.
14. Derendorf H, Hochhaus G, Rohatagi S, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-305.
15. Falcoz C, Kirby SM, Smith J, Olsson P, Ventresca GP. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 1996;9 Suppl 23:1628.
16. Falcoz C, Mackie AE, McDowall J, et al. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41;459-460P.
17. Barnes PJ, Pedersen S, Busse W. Efficacy and safety of inhaled corticosteroids: new developments. Am J Respir Crit Care Med 1998;157:1-53.
18. Pedersen S, Schleimer R, Busse W, O'Byrne P, editors. Efficacy and safety of inhaled corticosteroids in children. In: Topical glucocorticoids in asthma - mechanisms and clinical actions. New York: Marcel Dekker, 1996:551-560.
19. Pedersen S, Silverman M, editors. Aerosols and other devices. In: Childhood asthma and other wheezing disorders. London: Chapman & Hall Medical, 1995:313-332.
20. Pedersen S, Barnes PJ, Grunstein M, Leff A, Woolcock AJ, editors. Delivery systems in children. In: Asthma. New York; Lippincott-Raven, 1995:1915-1930.
21. Agertoft L, Andersen A, Weibull E, Pedersen S. Systemic availability and pharmacokinetics of nebulized budesonide in pre-school children with asthma. Arch Dis Child 1999 (in press).
22. Brattsand R, Axelsson BI, Barnes PJ, editors. New inhaled glucorticosteroids. In: New drugs for asthma. London: IBC Technical Services, 1992:193-208.
23. Högger P, Rawert I, Rohdewald P. Dissolution, tissue binding and kinetics of receptor binding of inhaled glucocorticoids. Eur Respir J 1993;6 Suppl 17:5848.
24. Miller Larsson A, Mattson H, Ohlsson D, et al. Prolonged release from the airway tissue of glucocorticoids budesonide and fluticasone propionate as compared to beclomethasone dipropionate and hydrocortisone. Am J Respir Crit Care Med 1994;149 Suppl:A466.
25. Miller Larsson A, Hjertberg E, Mattsson H, et al. Reversible fatty acid conjugation of budesonide results in a prolonged retention in airway tissue as compared to fluticasone propionate [Abstract]. Am J Respir Crit Care Med 1997;155:A353.
26. Miller Larsson A, Jansson P, Runsiröm A-B, et al. Reversible fatty acid conjugation of budesonide results in a prolonged topical anti-inflammatory activity in airways as compared to fluticasone propionate [Abstract]. Am J Respir Crit Care Med 1997;155:A353.
27. Wieslander EI, Delander EL, Järkelid L, et al. Reversible fatty acid conjugation of budesonide results in prolonged anti-inflammatory activity in vitro as compared to fluticasone propionate [Abstract]. Am J Respir Crit Care Med 1997;155:A353.
28. R after repeat doses in healthy subjects and asthmatic patients. J Allergy Clin Immunol 1997;99(no 1 pt 2):S505.
29. Harter JG, Reddy WJ, Thorn GW. Studies on an intermittent corticosteroid dosage regimen. N Engl J Med 1963;269:591-596.
30. Heuck C, Wolthers OD. Short term growth assessment of once versus twice daily inhaled budesonide in children with asthma. Eur Respir J 1995;8 Suppl 19:470s.
31. Agertoft L, Wolthers O, Fuglsang G, Pedersen S. Nasal powder administration of budesonide for seasonal rhinitis in children and adolescents. Pediatr Allergy Immunol 1993;4:152-156.
32. Pedersen S, Steffensen G, Ekman I, Tönnesson M, Borgä O. Pharmacokinetics of budesonide in children with asthma. Eur J Clin Pharmacol 1987;31:579-582.
33. Pedersen S, Steffensen G, Ekman I, et al, editors. Bioavailability of inhaled budesonide in children with asthma. In: Childhood asthma. Amsterdam: Excerpta Medica, 1986:29-34.
34. Pedersen S, Steffensen G, Ohlsson SV. The influence of orally deposited budesonide on the systemic availability of budesonide after inhalation from a Turbuhaler. Br J Clin Pharmacol 1993;36:211-214.
35. Place VA, Velazquez J, Burdick KH. Precise evaluation of topically applied corticosteroid potency. Modification of the Stoughton-McKenzie assay. Arch Dermatol 1970;101:531-537.
36. McKenzie AW, Stoughton RB. Method for comparing percutaneous absorption of steroids. Arch Dermatol 1962;86:608-610.
37. Brattsand R, Axelsson BI. New inhaled glucocorticosteroids. In: Barnes PJ, editor. New drugs for asthma. Vol. 2, London: 1992:193-208.
38. Phillipps GH. Structure-activity relationships of topically active steroids: the selection of fluticasone propionate. Respir Med 1990;84:19-23.
39. Johansson S, Andersson KE, Brattsand R, Gruvstad E, Hedner P. Topical and systemic glucocorticosteroid potencies of budesonide and beclomethasone dipropionate in man. Eur J Clin Pharmacol 1982;22:523-529.
40. Gruvstad E, Bengtsson B. A comparison of a new steroid, budesonide, with other topical corticosteroids in the vasoconstriction assay. Drugs Exp Clin Res 1980;6:385-390.
41. English AF, Neate MS, Quint DJ, Sareen M. Biological activities of some corticosteroids used in asthma. Am J Respir Crit Care Med 1994;149:A212.
42. Andersson N, Klint S, Randwall G, Wiren JE. Equipotency of budesonide and fluticasone propionate in the vasoconstriction assay. Am J Respir Crit Care Med 1994;149:A467.
43. Johnson M. Anti-inflammatory properties of fluticasone propionate. Int Arch Allergy Immunol 1995;107:439-440.
44. Stern MA, Dahl R, Nielsen LP, Pedersen B, Schrewelius C. A comparison of aqueous suspensions of budesonide nasal spray (128 micrograms once daily and 256 micrograms once daily) and fluticasone propionate nasal spray (200 micrograms once daily) in the treatment of adult patients with seasonal allergic rhinitis. Am J Rhinol 1997;11:323-330.
45. Andersson M, Berglund R, Greiff L, et al. A comparison of budesonide nasal dry powder with fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis. Rhinology 1995;33:18-22.
46. Day J, Carrillo T, Schrewelius C. A placebo-controlled study comparing aqueous suspensions of budesonide (BUD) and fluticasone propionate (FP) in patients with perennial allergic rhinitis. Presented at the Week of the Nose, Ghent, Belgium, 8-12 Sept 1996 (ISIAN, Philadelphia).
47. Pedersen S, O'Byrne P. A comparison of the efficacy and safety of inhaled corticosteroids in asthma. Allergy 1997;52: Suppl 39:1-34.
48. Pedersen S, Hansen OR. Budesonide treatment of moderate and severe asthma in children. A dose response study. J Allergy Clin Immunol 1995;1:29-33.
49. Kraan J, Koeter GH, van der Mark TW, et al. Dosage and time effects of inhaled budesonide un bronchial hyperreactivity. Am Rev Respir Dis 1988;137:44-48.
50. van Essen-Zandvliet E, Hughes MD, Waalkens HJ, Duiverman E, Pocock SJ, Kerrebijn K. Effects of 22 months of treatment with inhaled corticosteroids and/ or beta-2-agonists on lung function, airway responsiveness and symptoms in children with asthma. Am Rev Respir Dis 1992;146:547-554.
51. Agertoft L, Pedersen S. Importance of training for correct Turbuhaler use in preschool children. Acta Paediatr Scand 1998;87:842-847.